We could all use some extra cash on hand, and this dividend stock could create loads of it. The post Invest $15,000, Create ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

IGM Financial Inc. (TSE:IGM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research ...

IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...

Fintel reports that on January 13, 2025, JP Morgan upgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...

On Friday, IGM Biosciences Inc (IGMS) stock saw a decline, ending the day at $2.09 which represents a decrease of $-4.11 or -66.29% from the prior close of $6.2. The stock opened at $2.01 and touched ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Werfen today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Aptiva® ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.